nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—CHRM3—ureter—urinary bladder cancer	0.0867	0.318	CbGeAlD
Darifenacin—CHRM3—muscle of abdomen—urinary bladder cancer	0.0624	0.229	CbGeAlD
Darifenacin—CYP3A4—urine—urinary bladder cancer	0.0155	0.0567	CbGeAlD
Darifenacin—CYP2D6—urine—urinary bladder cancer	0.0152	0.0558	CbGeAlD
Darifenacin—CHRM5—epithelium—urinary bladder cancer	0.0133	0.0487	CbGeAlD
Darifenacin—CHRM2—prostate gland—urinary bladder cancer	0.0124	0.0455	CbGeAlD
Darifenacin—CHRM1—prostate gland—urinary bladder cancer	0.0113	0.0414	CbGeAlD
Darifenacin—CHRM3—prostate gland—urinary bladder cancer	0.0101	0.037	CbGeAlD
Darifenacin—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00716	0.0262	CbGeAlD
Darifenacin—CHRM3—renal system—urinary bladder cancer	0.00689	0.0252	CbGeAlD
Darifenacin—CHRM3—urethra—urinary bladder cancer	0.00677	0.0248	CbGeAlD
Darifenacin—CHRM1—female reproductive system—urinary bladder cancer	0.00617	0.0226	CbGeAlD
Darifenacin—CHRM3—female reproductive system—urinary bladder cancer	0.00552	0.0202	CbGeAlD
Darifenacin—CYP3A4—renal system—urinary bladder cancer	0.00379	0.0139	CbGeAlD
Darifenacin—CYP2D6—renal system—urinary bladder cancer	0.00373	0.0137	CbGeAlD
Darifenacin—CYP3A4—female reproductive system—urinary bladder cancer	0.00303	0.0111	CbGeAlD
Darifenacin—CYP2D6—female reproductive system—urinary bladder cancer	0.00298	0.0109	CbGeAlD
Darifenacin—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.00133	0.00183	CcSEcCtD
Darifenacin—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00133	0.00182	CcSEcCtD
Darifenacin—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00133	0.00182	CcSEcCtD
Darifenacin—Somnolence—Fluorouracil—urinary bladder cancer	0.00132	0.00182	CcSEcCtD
Darifenacin—Face oedema—Doxorubicin—urinary bladder cancer	0.00132	0.00181	CcSEcCtD
Darifenacin—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00131	0.0018	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00131	0.0018	CcSEcCtD
Darifenacin—Confusional state—Etoposide—urinary bladder cancer	0.0013	0.00179	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.0013	0.00179	CcSEcCtD
Darifenacin—Pain—Gemcitabine—urinary bladder cancer	0.00129	0.00178	CcSEcCtD
Darifenacin—Constipation—Gemcitabine—urinary bladder cancer	0.00129	0.00178	CcSEcCtD
Darifenacin—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00129	0.00178	CcSEcCtD
Darifenacin—Asthenia—Thiotepa—urinary bladder cancer	0.00129	0.00178	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00129	0.00177	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00128	0.00177	CcSEcCtD
Darifenacin—Infection—Etoposide—urinary bladder cancer	0.00128	0.00177	CcSEcCtD
Darifenacin—Influenza—Epirubicin—urinary bladder cancer	0.00127	0.00175	CcSEcCtD
Darifenacin—Pruritus—Thiotepa—urinary bladder cancer	0.00127	0.00175	CcSEcCtD
Darifenacin—Pain—Fluorouracil—urinary bladder cancer	0.00127	0.00175	CcSEcCtD
Darifenacin—Tachycardia—Etoposide—urinary bladder cancer	0.00126	0.00173	CcSEcCtD
Darifenacin—Dyspnoea—Cisplatin—urinary bladder cancer	0.00126	0.00173	CcSEcCtD
Darifenacin—Skin disorder—Etoposide—urinary bladder cancer	0.00126	0.00173	CcSEcCtD
Darifenacin—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00125	0.00172	CcSEcCtD
Darifenacin—Dry skin—Doxorubicin—urinary bladder cancer	0.00125	0.00172	CcSEcCtD
Darifenacin—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00125	0.00172	CcSEcCtD
Darifenacin—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00125	0.00172	CcSEcCtD
Darifenacin—Breast disorder—Doxorubicin—urinary bladder cancer	0.00123	0.0017	CcSEcCtD
Darifenacin—Diarrhoea—Thiotepa—urinary bladder cancer	0.00123	0.00169	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00123	0.00169	CcSEcCtD
Darifenacin—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00123	0.00169	CcSEcCtD
Darifenacin—Bronchitis—Epirubicin—urinary bladder cancer	0.00123	0.00169	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00122	0.00168	CcSEcCtD
Darifenacin—Infestation NOS—Methotrexate—urinary bladder cancer	0.00121	0.00167	CcSEcCtD
Darifenacin—Infestation—Methotrexate—urinary bladder cancer	0.00121	0.00167	CcSEcCtD
Darifenacin—Pain—Cisplatin—urinary bladder cancer	0.00121	0.00166	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.0012	0.00165	CcSEcCtD
Darifenacin—Dizziness—Thiotepa—urinary bladder cancer	0.00119	0.00164	CcSEcCtD
Darifenacin—Stomatitis—Methotrexate—urinary bladder cancer	0.00118	0.00163	CcSEcCtD
Darifenacin—Influenza—Doxorubicin—urinary bladder cancer	0.00118	0.00162	CcSEcCtD
Darifenacin—Sweating—Methotrexate—urinary bladder cancer	0.00116	0.0016	CcSEcCtD
Darifenacin—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00116	0.0016	CcSEcCtD
Darifenacin—Weight increased—Epirubicin—urinary bladder cancer	0.00116	0.00159	CcSEcCtD
Darifenacin—Dyspnoea—Etoposide—urinary bladder cancer	0.00115	0.00158	CcSEcCtD
Darifenacin—Somnolence—Etoposide—urinary bladder cancer	0.00115	0.00158	CcSEcCtD
Darifenacin—Vomiting—Thiotepa—urinary bladder cancer	0.00114	0.00157	CcSEcCtD
Darifenacin—Infestation NOS—Epirubicin—urinary bladder cancer	0.00114	0.00156	CcSEcCtD
Darifenacin—Infestation—Epirubicin—urinary bladder cancer	0.00114	0.00156	CcSEcCtD
Darifenacin—Rash—Thiotepa—urinary bladder cancer	0.00113	0.00156	CcSEcCtD
Darifenacin—Bronchitis—Doxorubicin—urinary bladder cancer	0.00113	0.00156	CcSEcCtD
Darifenacin—Dermatitis—Thiotepa—urinary bladder cancer	0.00113	0.00156	CcSEcCtD
Darifenacin—Headache—Thiotepa—urinary bladder cancer	0.00113	0.00155	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00112	0.00153	CcSEcCtD
Darifenacin—Stomatitis—Epirubicin—urinary bladder cancer	0.00111	0.00152	CcSEcCtD
Darifenacin—Pain—Etoposide—urinary bladder cancer	0.00111	0.00152	CcSEcCtD
Darifenacin—Constipation—Etoposide—urinary bladder cancer	0.00111	0.00152	CcSEcCtD
Darifenacin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.0011	0.00152	CcSEcCtD
Darifenacin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.0011	0.00151	CcSEcCtD
Darifenacin—Sweating—Epirubicin—urinary bladder cancer	0.00109	0.0015	CcSEcCtD
Darifenacin—Asthenia—Gemcitabine—urinary bladder cancer	0.00109	0.00149	CcSEcCtD
Darifenacin—Pharyngitis—Methotrexate—urinary bladder cancer	0.00108	0.00149	CcSEcCtD
Darifenacin—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00108	0.00148	CcSEcCtD
Darifenacin—Weight increased—Doxorubicin—urinary bladder cancer	0.00107	0.00148	CcSEcCtD
Darifenacin—Pruritus—Gemcitabine—urinary bladder cancer	0.00107	0.00147	CcSEcCtD
Darifenacin—Nausea—Thiotepa—urinary bladder cancer	0.00107	0.00147	CcSEcCtD
Darifenacin—Urethral disorder—Methotrexate—urinary bladder cancer	0.00107	0.00147	CcSEcCtD
Darifenacin—Sinusitis—Epirubicin—urinary bladder cancer	0.00107	0.00147	CcSEcCtD
Darifenacin—Feeling abnormal—Etoposide—urinary bladder cancer	0.00107	0.00146	CcSEcCtD
Darifenacin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00106	0.00145	CcSEcCtD
Darifenacin—Pruritus—Fluorouracil—urinary bladder cancer	0.00105	0.00145	CcSEcCtD
Darifenacin—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00105	0.00145	CcSEcCtD
Darifenacin—Infestation—Doxorubicin—urinary bladder cancer	0.00105	0.00145	CcSEcCtD
Darifenacin—Visual impairment—Methotrexate—urinary bladder cancer	0.00105	0.00144	CcSEcCtD
Darifenacin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00104	0.00143	CcSEcCtD
Darifenacin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00104	0.00142	CcSEcCtD
Darifenacin—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00103	0.00142	CcSEcCtD
Darifenacin—Stomatitis—Doxorubicin—urinary bladder cancer	0.00102	0.00141	CcSEcCtD
Darifenacin—Rhinitis—Epirubicin—urinary bladder cancer	0.00102	0.00141	CcSEcCtD
Darifenacin—Abdominal pain—Etoposide—urinary bladder cancer	0.00102	0.00141	CcSEcCtD
Darifenacin—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00102	0.00141	CcSEcCtD
Darifenacin—Eye disorder—Methotrexate—urinary bladder cancer	0.00102	0.0014	CcSEcCtD
Darifenacin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00102	0.0014	CcSEcCtD
Darifenacin—Asthenia—Cisplatin—urinary bladder cancer	0.00101	0.00139	CcSEcCtD
Darifenacin—Pharyngitis—Epirubicin—urinary bladder cancer	0.00101	0.00139	CcSEcCtD
Darifenacin—Sweating—Doxorubicin—urinary bladder cancer	0.00101	0.00139	CcSEcCtD
Darifenacin—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00101	0.00139	CcSEcCtD
Darifenacin—Oedema peripheral—Epirubicin—urinary bladder cancer	0.001	0.00138	CcSEcCtD
Darifenacin—Urethral disorder—Epirubicin—urinary bladder cancer	0.001	0.00137	CcSEcCtD
Darifenacin—Angiopathy—Methotrexate—urinary bladder cancer	0.000989	0.00136	CcSEcCtD
Darifenacin—Sinusitis—Doxorubicin—urinary bladder cancer	0.000986	0.00136	CcSEcCtD
Darifenacin—Dizziness—Fluorouracil—urinary bladder cancer	0.000984	0.00135	CcSEcCtD
Darifenacin—Visual impairment—Epirubicin—urinary bladder cancer	0.000983	0.00135	CcSEcCtD
Darifenacin—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000982	0.00135	CcSEcCtD
Darifenacin—Diarrhoea—Cisplatin—urinary bladder cancer	0.000965	0.00133	CcSEcCtD
Darifenacin—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000964	0.00133	CcSEcCtD
Darifenacin—Vomiting—Gemcitabine—urinary bladder cancer	0.000962	0.00132	CcSEcCtD
Darifenacin—Mental disorder—Methotrexate—urinary bladder cancer	0.000955	0.00131	CcSEcCtD
Darifenacin—Rash—Gemcitabine—urinary bladder cancer	0.000954	0.00131	CcSEcCtD
Darifenacin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000953	0.00131	CcSEcCtD
Darifenacin—Eye disorder—Epirubicin—urinary bladder cancer	0.000953	0.00131	CcSEcCtD
Darifenacin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000952	0.00131	CcSEcCtD
Darifenacin—Headache—Gemcitabine—urinary bladder cancer	0.000948	0.0013	CcSEcCtD
Darifenacin—Vomiting—Fluorouracil—urinary bladder cancer	0.000946	0.0013	CcSEcCtD
Darifenacin—Rhinitis—Doxorubicin—urinary bladder cancer	0.000946	0.0013	CcSEcCtD
Darifenacin—Rash—Fluorouracil—urinary bladder cancer	0.000938	0.00129	CcSEcCtD
Darifenacin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000937	0.00129	CcSEcCtD
Darifenacin—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000936	0.00129	CcSEcCtD
Darifenacin—Headache—Fluorouracil—urinary bladder cancer	0.000932	0.00128	CcSEcCtD
Darifenacin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000932	0.00128	CcSEcCtD
Darifenacin—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00093	0.00128	CcSEcCtD
Darifenacin—Dysgeusia—Methotrexate—urinary bladder cancer	0.000929	0.00128	CcSEcCtD
Darifenacin—Asthenia—Etoposide—urinary bladder cancer	0.000927	0.00128	CcSEcCtD
Darifenacin—Angiopathy—Epirubicin—urinary bladder cancer	0.000925	0.00127	CcSEcCtD
Darifenacin—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000925	0.00127	CcSEcCtD
Darifenacin—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000919	0.00126	CcSEcCtD
Darifenacin—Back pain—Methotrexate—urinary bladder cancer	0.000918	0.00126	CcSEcCtD
Darifenacin—Pruritus—Etoposide—urinary bladder cancer	0.000914	0.00126	CcSEcCtD
Darifenacin—Visual impairment—Doxorubicin—urinary bladder cancer	0.000909	0.00125	CcSEcCtD
Darifenacin—Nausea—Gemcitabine—urinary bladder cancer	0.000899	0.00124	CcSEcCtD
Darifenacin—Vomiting—Cisplatin—urinary bladder cancer	0.000897	0.00123	CcSEcCtD
Darifenacin—Vision blurred—Methotrexate—urinary bladder cancer	0.000894	0.00123	CcSEcCtD
Darifenacin—Mental disorder—Epirubicin—urinary bladder cancer	0.000893	0.00123	CcSEcCtD
Darifenacin—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000892	0.00123	CcSEcCtD
Darifenacin—Rash—Cisplatin—urinary bladder cancer	0.00089	0.00122	CcSEcCtD
Darifenacin—Dermatitis—Cisplatin—urinary bladder cancer	0.000889	0.00122	CcSEcCtD
Darifenacin—Diarrhoea—Etoposide—urinary bladder cancer	0.000884	0.00122	CcSEcCtD
Darifenacin—Nausea—Fluorouracil—urinary bladder cancer	0.000884	0.00122	CcSEcCtD
Darifenacin—Eye disorder—Doxorubicin—urinary bladder cancer	0.000882	0.00121	CcSEcCtD
Darifenacin—Flatulence—Epirubicin—urinary bladder cancer	0.000875	0.0012	CcSEcCtD
Darifenacin—Dysgeusia—Epirubicin—urinary bladder cancer	0.000869	0.0012	CcSEcCtD
Darifenacin—Back pain—Epirubicin—urinary bladder cancer	0.000859	0.00118	CcSEcCtD
Darifenacin—Angiopathy—Doxorubicin—urinary bladder cancer	0.000856	0.00118	CcSEcCtD
Darifenacin—Dizziness—Etoposide—urinary bladder cancer	0.000855	0.00118	CcSEcCtD
Darifenacin—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00085	0.00117	CcSEcCtD
Darifenacin—Nausea—Cisplatin—urinary bladder cancer	0.000838	0.00115	CcSEcCtD
Darifenacin—Vision blurred—Epirubicin—urinary bladder cancer	0.000837	0.00115	CcSEcCtD
Darifenacin—Cough—Methotrexate—urinary bladder cancer	0.000828	0.00114	CcSEcCtD
Darifenacin—Mental disorder—Doxorubicin—urinary bladder cancer	0.000827	0.00114	CcSEcCtD
Darifenacin—Vomiting—Etoposide—urinary bladder cancer	0.000822	0.00113	CcSEcCtD
Darifenacin—Rash—Etoposide—urinary bladder cancer	0.000815	0.00112	CcSEcCtD
Darifenacin—Dermatitis—Etoposide—urinary bladder cancer	0.000814	0.00112	CcSEcCtD
Darifenacin—Headache—Etoposide—urinary bladder cancer	0.00081	0.00111	CcSEcCtD
Darifenacin—Flatulence—Doxorubicin—urinary bladder cancer	0.000809	0.00111	CcSEcCtD
Darifenacin—Arthralgia—Methotrexate—urinary bladder cancer	0.000808	0.00111	CcSEcCtD
Darifenacin—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000804	0.00111	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000802	0.0011	CcSEcCtD
Darifenacin—Syncope—Epirubicin—urinary bladder cancer	0.000796	0.00109	CcSEcCtD
Darifenacin—Back pain—Doxorubicin—urinary bladder cancer	0.000795	0.00109	CcSEcCtD
Darifenacin—Palpitations—Epirubicin—urinary bladder cancer	0.000784	0.00108	CcSEcCtD
Darifenacin—Confusional state—Methotrexate—urinary bladder cancer	0.000781	0.00107	CcSEcCtD
Darifenacin—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00078	0.00107	CcSEcCtD
Darifenacin—Cough—Epirubicin—urinary bladder cancer	0.000775	0.00107	CcSEcCtD
Darifenacin—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000774	0.00106	CcSEcCtD
Darifenacin—Vision blurred—Doxorubicin—urinary bladder cancer	0.000774	0.00106	CcSEcCtD
Darifenacin—Infection—Methotrexate—urinary bladder cancer	0.000769	0.00106	CcSEcCtD
Darifenacin—Nausea—Etoposide—urinary bladder cancer	0.000768	0.00106	CcSEcCtD
Darifenacin—Hypertension—Epirubicin—urinary bladder cancer	0.000766	0.00105	CcSEcCtD
Darifenacin—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000759	0.00104	CcSEcCtD
Darifenacin—Arthralgia—Epirubicin—urinary bladder cancer	0.000756	0.00104	CcSEcCtD
Darifenacin—Skin disorder—Methotrexate—urinary bladder cancer	0.000752	0.00103	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000751	0.00103	CcSEcCtD
Darifenacin—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000748	0.00103	CcSEcCtD
Darifenacin—Dry mouth—Epirubicin—urinary bladder cancer	0.000739	0.00102	CcSEcCtD
Darifenacin—Syncope—Doxorubicin—urinary bladder cancer	0.000737	0.00101	CcSEcCtD
Darifenacin—Confusional state—Epirubicin—urinary bladder cancer	0.000731	0.001	CcSEcCtD
Darifenacin—Palpitations—Doxorubicin—urinary bladder cancer	0.000726	0.000998	CcSEcCtD
Darifenacin—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000725	0.000996	CcSEcCtD
Darifenacin—Oedema—Epirubicin—urinary bladder cancer	0.000725	0.000996	CcSEcCtD
Darifenacin—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000722	0.000993	CcSEcCtD
Darifenacin—Infection—Epirubicin—urinary bladder cancer	0.00072	0.00099	CcSEcCtD
Darifenacin—Cough—Doxorubicin—urinary bladder cancer	0.000717	0.000986	CcSEcCtD
Darifenacin—Shock—Epirubicin—urinary bladder cancer	0.000713	0.00098	CcSEcCtD
Darifenacin—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000711	0.000977	CcSEcCtD
Darifenacin—Hypertension—Doxorubicin—urinary bladder cancer	0.000709	0.000975	CcSEcCtD
Darifenacin—Tachycardia—Epirubicin—urinary bladder cancer	0.000707	0.000972	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000705	0.00097	CcSEcCtD
Darifenacin—Skin disorder—Epirubicin—urinary bladder cancer	0.000704	0.000968	CcSEcCtD
Darifenacin—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.0007	0.000963	CcSEcCtD
Darifenacin—Insomnia—Methotrexate—urinary bladder cancer	0.0007	0.000963	CcSEcCtD
Darifenacin—Arthralgia—Doxorubicin—urinary bladder cancer	0.000699	0.000962	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000694	0.000955	CcSEcCtD
Darifenacin—Dyspnoea—Methotrexate—urinary bladder cancer	0.00069	0.000949	CcSEcCtD
Darifenacin—Somnolence—Methotrexate—urinary bladder cancer	0.000688	0.000947	CcSEcCtD
Darifenacin—Dry mouth—Doxorubicin—urinary bladder cancer	0.000684	0.000941	CcSEcCtD
Darifenacin—Dyspepsia—Methotrexate—urinary bladder cancer	0.000681	0.000937	CcSEcCtD
Darifenacin—Confusional state—Doxorubicin—urinary bladder cancer	0.000676	0.00093	CcSEcCtD
Darifenacin—Oedema—Doxorubicin—urinary bladder cancer	0.00067	0.000922	CcSEcCtD
Darifenacin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00067	0.000922	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000668	0.000919	CcSEcCtD
Darifenacin—Infection—Doxorubicin—urinary bladder cancer	0.000666	0.000916	CcSEcCtD
Darifenacin—Pain—Methotrexate—urinary bladder cancer	0.000662	0.000911	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00066	0.000908	CcSEcCtD
Darifenacin—Shock—Doxorubicin—urinary bladder cancer	0.00066	0.000907	CcSEcCtD
Darifenacin—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000657	0.000904	CcSEcCtD
Darifenacin—Insomnia—Epirubicin—urinary bladder cancer	0.000655	0.000901	CcSEcCtD
Darifenacin—Tachycardia—Doxorubicin—urinary bladder cancer	0.000654	0.0009	CcSEcCtD
Darifenacin—Skin disorder—Doxorubicin—urinary bladder cancer	0.000651	0.000896	CcSEcCtD
Darifenacin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000648	0.000891	CcSEcCtD
Darifenacin—Dyspnoea—Epirubicin—urinary bladder cancer	0.000646	0.000888	CcSEcCtD
Darifenacin—Somnolence—Epirubicin—urinary bladder cancer	0.000644	0.000886	CcSEcCtD
Darifenacin—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000638	0.000877	CcSEcCtD
Darifenacin—Dyspepsia—Epirubicin—urinary bladder cancer	0.000638	0.000877	CcSEcCtD
Darifenacin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000633	0.000871	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000625	0.00086	CcSEcCtD
Darifenacin—Pain—Epirubicin—urinary bladder cancer	0.00062	0.000852	CcSEcCtD
Darifenacin—Constipation—Epirubicin—urinary bladder cancer	0.00062	0.000852	CcSEcCtD
Darifenacin—Abdominal pain—Methotrexate—urinary bladder cancer	0.000612	0.000842	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000611	0.00084	CcSEcCtD
Darifenacin—Insomnia—Doxorubicin—urinary bladder cancer	0.000606	0.000834	CcSEcCtD
Darifenacin—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000598	0.000822	CcSEcCtD
Darifenacin—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000597	0.000821	CcSEcCtD
Darifenacin—Somnolence—Doxorubicin—urinary bladder cancer	0.000596	0.00082	CcSEcCtD
Darifenacin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000592	0.000815	CcSEcCtD
Darifenacin—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00059	0.000812	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000579	0.000796	CcSEcCtD
Darifenacin—Constipation—Doxorubicin—urinary bladder cancer	0.000573	0.000788	CcSEcCtD
Darifenacin—Pain—Doxorubicin—urinary bladder cancer	0.000573	0.000788	CcSEcCtD
Darifenacin—Abdominal pain—Epirubicin—urinary bladder cancer	0.000573	0.000788	CcSEcCtD
Darifenacin—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00057	0.000784	CcSEcCtD
Darifenacin—Asthenia—Methotrexate—urinary bladder cancer	0.000555	0.000764	CcSEcCtD
Darifenacin—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000552	0.00076	CcSEcCtD
Darifenacin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000548	0.000754	CcSEcCtD
Darifenacin—Pruritus—Methotrexate—urinary bladder cancer	0.000548	0.000753	CcSEcCtD
Darifenacin—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000534	0.000734	CcSEcCtD
Darifenacin—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00053	0.000729	CcSEcCtD
Darifenacin—Diarrhoea—Methotrexate—urinary bladder cancer	0.00053	0.000729	CcSEcCtD
Darifenacin—Asthenia—Epirubicin—urinary bladder cancer	0.00052	0.000715	CcSEcCtD
Darifenacin—Pruritus—Epirubicin—urinary bladder cancer	0.000513	0.000705	CcSEcCtD
Darifenacin—Dizziness—Methotrexate—urinary bladder cancer	0.000512	0.000704	CcSEcCtD
Darifenacin—Diarrhoea—Epirubicin—urinary bladder cancer	0.000496	0.000682	CcSEcCtD
Darifenacin—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000494	0.000679	CcSEcCtD
Darifenacin—Vomiting—Methotrexate—urinary bladder cancer	0.000492	0.000677	CcSEcCtD
Darifenacin—Rash—Methotrexate—urinary bladder cancer	0.000488	0.000671	CcSEcCtD
Darifenacin—Dermatitis—Methotrexate—urinary bladder cancer	0.000488	0.000671	CcSEcCtD
Darifenacin—Headache—Methotrexate—urinary bladder cancer	0.000485	0.000667	CcSEcCtD
Darifenacin—Asthenia—Doxorubicin—urinary bladder cancer	0.000481	0.000661	CcSEcCtD
Darifenacin—Dizziness—Epirubicin—urinary bladder cancer	0.000479	0.000659	CcSEcCtD
Darifenacin—Pruritus—Doxorubicin—urinary bladder cancer	0.000474	0.000652	CcSEcCtD
Darifenacin—Vomiting—Epirubicin—urinary bladder cancer	0.000461	0.000634	CcSEcCtD
Darifenacin—Nausea—Methotrexate—urinary bladder cancer	0.00046	0.000632	CcSEcCtD
Darifenacin—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000459	0.000631	CcSEcCtD
Darifenacin—Rash—Epirubicin—urinary bladder cancer	0.000457	0.000628	CcSEcCtD
Darifenacin—Dermatitis—Epirubicin—urinary bladder cancer	0.000456	0.000628	CcSEcCtD
Darifenacin—Headache—Epirubicin—urinary bladder cancer	0.000454	0.000624	CcSEcCtD
Darifenacin—Dizziness—Doxorubicin—urinary bladder cancer	0.000443	0.00061	CcSEcCtD
Darifenacin—Nausea—Epirubicin—urinary bladder cancer	0.00043	0.000592	CcSEcCtD
Darifenacin—Vomiting—Doxorubicin—urinary bladder cancer	0.000426	0.000586	CcSEcCtD
Darifenacin—Rash—Doxorubicin—urinary bladder cancer	0.000423	0.000581	CcSEcCtD
Darifenacin—Dermatitis—Doxorubicin—urinary bladder cancer	0.000422	0.000581	CcSEcCtD
Darifenacin—Headache—Doxorubicin—urinary bladder cancer	0.00042	0.000578	CcSEcCtD
Darifenacin—Nausea—Doxorubicin—urinary bladder cancer	0.000398	0.000548	CcSEcCtD
